PCV-2 Vaccine

PCV-2 - Disease Description

PCV2 is a major swine pathogen causing PCV-associated disease, including post-weaning wasting, reduced daily weight gain, lymphoid depletion/ immunosuppression, respiratory disease complex, reproductive failure, higher susceptibility to co-infections and, in severe clinical cases, high mortality among affected animals.

PCV2 is present in all major swine-producing regions, including the USA, China, Japan, South Korea and the EU; current molecular epidemiology is dominated by PCV2d, while PCV2a and PCV2b continue to circulate, making broad cross-genotype protection important for a world-wide vaccine.

Current official country-by-country PCV2 loss statistics are not routinely reported after broad vaccination, but published benchmarks show large economic exposure: historical US losses were estimated at about US$3–4 per pig, with peaks up to US$20 per pig; pre-vaccine EU losses were estimated at €562–900 million/year, and England alone at about £52.6–55.7 million/year; given current pork production scale — China ~59.4 Mt, EU ~21.6–22.0 Mt, USA ~12.5 Mt, Japan ~1.27 Mt, South Korea ~1.43 Mt and world production above 116 Mt — residual or subclinical PCV2 losses can still represent hundreds of millions to multi-billion-euro exposure globally, especially in China, the EU and the USA.